TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zelira Therapeutics ( (AU:ZLD) ) has issued an update.
Zelira Therapeutics announced a change in the interest of its director, Oludare Odumosu, involving the acquisition of 386,847 convertible notes. This change reflects the issuance of convertible notes to replace a Convertible Loan Agreement, which was approved by shareholders, potentially impacting the company’s financial structure and signaling strategic financial adjustments.
The most recent analyst rating on (AU:ZLD) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics Limited operates in the pharmaceutical industry, focusing on the development and commercialization of cannabinoid-based medicines. The company targets various therapeutic areas, including pain management and sleep disorders, aiming to leverage the growing interest in medical cannabis products.
Average Trading Volume: 6,042
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.93M
Find detailed analytics on ZLD stock on TipRanks’ Stock Analysis page.